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The expanding use of genomic technologies encompasses all phases of life, from the
embryo to the elderly, and even the posthumous phase. In this paper, we present the
spectrum of genomic healthcare applications, and describe their scope and challenges
at different stages of the life cycle. The integration of genomic technology into healthcare
presents unique ethical issues that challenge traditional aspects of healthcare delivery.
These challenges include the different definitions of utility as applied to genomic
information; the particular characteristics of genetic data that influence how it might be
protected, used and shared; and the difficulties applying existing models of informed
consent, and how new consent models might be needed.
Keywords: genomics, public health, healthcare, genomic testing, molecular diagnostics, genetic disease, clinical
utility, genomic data
INTRODUCTION
Genomic testing is used to diagnose, monitor, treat, predict and prevent disease, as well as promote
good health in individuals, across communities and whole populations. Technological advances
have allowed for greater integration of genomics into healthcare delivery, from screening and
molecular diagnostics, to the accurate detection of microbes, and the ability to prescribe and
monitor the efficacy of more precise therapeutics (1). The potential for increased use of genomic
testing in the health setting is available throughout the life cycle, including in preimplantation,
prenatal, neonatal, pediatric, adult, preconception, and posthumous settings (2). The person (who
is often, but not always, also the “patient”) should be firmly at the center of the genomics revolution
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in healthcare. We begin this review by discussing a variety
of current and emerging situations in which genomic testing
is being utilized in health settings, focusing on the ethical,
legal and social issues that apply at each point in the cycle-
of-life and at particular decision points relevant to specific
healthcare situations.
Subsequently, we focus on three main areas in which genomic
technology, which is considered to be both disruptive and
transformative to healthcare delivery (3), creates unique ethical
issues that can challenge traditional aspects of healthcare. We
summarize some of the key challenges and considerations
surrounding the increasing application of this technology,
highlighting issues that may arise when genomic tests are
used at different life cycle stages. Within this section, we
firstly outline the juxtaposition between clinical utility of a
genomic test with personal and other utility, particularly where
genomic testing is utilized in non-clinical settings (4). Related
to questions around the utility of testing are issues surrounding
the limited ability to interpret incidental findings and variants of
unknown significance, which presents ethical challenges for the
responsibility to return such results to patients (5).
Secondly, we consider how the personal nature of genomic
data is such that it can never be truly de-identified. This
creates potential issues around data storage and sharing; however,
integral to this is the necessity to share genomic information to
allow for advancement of knowledge of the etiology of disease
(6). Furthermore, appropriate reference genomes are critically
important for capturing the genomic diversity of the population
being tested (7) so as to deliver equitable healthcare.
Finally, we discuss how genomic testing can challenge
traditional models of informed consent in an environment where
online DNA tests are available, where genomic testing is being
increasingly utilized for individuals who are unable to consent,
and where re-interrogation of stored genomic data is possible
(8). For the purposes of this review, the term “genomics” is used
to encompass both genetics (individual genes) and genomics (all
genes in a genome).
CURRENT AND EMERGING
APPLICATIONS OF GENOMIC TESTING
ACROSS THE LIFE CYCLE
Genomic testing in the healthcare context can be applied in a
multitude of ways throughout the human lifespan (Table 1). The
application of massively parallel sequencing is expanding across
different healthcare domains. This technique allows for the
concurrent sequencing of numerous DNA fragments, enabling
multiple loci to be investigated at one time and consequently,
more efficient and cost-effective genomic analysis. Most of the
current and emerging uses of genomic healthcare technology
involve analyses for screening, diagnostic or prognostic
purposes; testing to guide and evaluate treatment options; and
identification and tracking of human disease-causing pathogens.
Furthermore, genomic technology is increasingly available
outside of healthcare settings through personal genomics tests
that may be accessed directly by consumers, also known as
direct-to-consumer or personal DNA tests (13, 22). Genomic
sequencing technology has provided numerous benefits,
particularly the significant improvement in the provision rate
of molecular diagnoses (22). Continued developments with
massively parallel sequencing include greater sensitivity of
detecting previously difficult disease-causing deletions (23) and
growing ability to detect copy number variants (24).
Genomic technology has increasing potential to contribute
transformative new treatments in the form of genetic therapy.
Recently this was demonstrated in a research setting with
the treatment in utero of 3 fetuses affected with X-linked
hypohydrotic ectodermal dysplasia. In this study, prenatal
intervention occurred in the successful delivery of a recombinant
version of the previously absent protein (25). Also on the horizon
is the potential to use circulating tumor DNA in the blood or
urine to assist in the clinical diagnosis of cancer, potentially
alleviating the current reliance on invasive tissue sampling of
solid tumors (26, 27).
The potential for genomic technology to continually improve
the health and wellbeing of the population across the life cycle
is anticipated. Further genomic and associated phenotypic data
are integral for the advancement of knowledge and interpretation
of genomic variants, and in turn the understanding of disease
risk and disease etiology to inform better healthcare (6, 28, 29).
The benefits of genomic technology in healthcare go beyond
the immediate improvements in diagnosis and treatment, where
a diagnosis is the portal to best care, to contributions to
general understanding about disease and health and informing
appropriately targeted public health initiatives.
The future ability to utilize “big data,” not only for the
incorporation of genomic information but also other “-omic”
information (e.g., metabolomics, proteomics), epigenetic,
phenotypic, environmental and personal data, will depend on
data collection and sharing. Big data will allow more precise
healthcare, specifically healthcare that is tailored to individuals
(i.e., precision medicine), and will facilitate precision public
health interventions tailored to genetically identified population
subgroups (30, 31). Additionally, large, shared datasets are
likely to become even more important to further knowledge
about disease mechanisms for common and complex polygenic
diseases (29).
CHALLENGES AND CONSIDERATIONS
FOR GENOMIC APPLICATIONS ACROSS
THE LIFE CYCLE
As described above, application of genomic technology and new
genomic knowledge is being applied across the life cycle in both
clinical and wider healthcare settings. Importantly, although the
genomic technology itself may remain fairly consistent across
different applications, the scope of the test can differ in terms
of who is tested, for whom healthcare decisions are made about,
the types of tests available, the potential conditions that can be
identified, the clinical information available and the potential
consequences of false positives or false negatives (see Table 2).
Moreover, the issues surrounding utility, incidental findings and
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TABLE 1 | Current and emerging applications of genomic tests across the life cycle.
Type of test Description
Diagnostic Used to investigate the cause of an observed phenotype. Testing follows onset of patient symptomatology, a clinical discovery or a
positive screening test. Can be performed any time from in utero through to old age, and can be applied postmortem or
posthumously. May detect germline or somatic variants.
Microorganism genomics Involves testing the genomes of organisms that interact with and influence human health. Enables understanding and tracing of
infections, outbreaks and identification of genomic changes behind antimicrobial resistance. Emerging applications include
investigation of human microbiomes [e.g., lung, gut (9, 10)] and their influence on immunity, drug interactions, and disease expression
(11).
Newborn bloodspot
screening
Screening of newborns using blood collected by the Guthrie (heel prick) test. It typically detects the increased likelihood of the
newborn having one of a number of rare and serious genetic conditions for which clinical interventions are available. Screening
assays are typically biochemical, with a second line genomic test subsequently applied (possibly in conjunction with a clinical assay)
to confirm the disease diagnosis for some conditions. The number and types of conditions included in newborn bloodspot screening
programs varies around the world (12).
Personal/online DNA
tests/direct-to-consumer
Genomic tests available direct to consumers through companies, with services ranging from having little or no clinical oversight
through to comprehensive genetic counseling and clinician sign-off options (13). e.g., Ancestry.com, 23andMe, Genome.One,
Counsyl, Helix, and Color. Options include gene panels for carrier, newborn, and inherited cancers testing. Availability of these
services varies internationally.
Pharmacogenomics Screening for genetic variants that alter drug-response with the aim of informing drug dosages and regimens to improve drug efficacy
and patient compliance, whilst reducing side effects and avoiding life-threatening reactions.
Predictive/presymptomatic Performed to establish an at-risk individual’s predisposition to the development of a condition prior to symptoms onset. Traditionally
this type of predictive testing involves both pre- and post-test genetic counseling. Huntington’s disease provides a prototypical model.
Preimplantation genetic
diagnosis (PGD)
Screening embryos created via in vitro fertilization (IVF) procedures to select those without a particular genomic variant/s for
subsequent implantation. This follows identification of increased risk of the embryo having a genetic condition via molecular diagnosis
or carrier screening of the parent/s.
Preimplantation genetic
screening (PGS)
Screening embryos created via IVF procedures to select those without an identified chromosomal anomaly. This technique arose as
an embryo selection tool in combination with IVF for women of advanced maternal age or with a history of failed implantation in IVF, to
attempt to improve implantation rates for IVF cycles (14).
Prenatal/antenatal screening In utero screening of a fetus can guide reproductive choice, preparedness and early interventions. An expanding approach for
prenatal screening of genetic conditions is non-invasive prenatal screening (NIPS). From 10 weeks gestation, NIPS can be used to
screen for the same chromosomal conditions as the combined first trimester screening test, as well as additional chromosomal
disorders, by direct analysis of cell-free fetal DNA circulating in maternal blood. Although NIPS is non-invasive and is more accurate
screening tool for these genetic conditions (15, 16), it is currently greater in cost than the combined first trimester screening test.
Women who opt for NIPS over combined first trimester screening are still recommended to have an ultrasound (17), as these may
detect pregnancy/fetal abnormalities not screened for by NIPS.
Prognostic Utilizes gene variant/s or expression information to predict disease progression, severity and outcomes, as well as optimize and
monitor therapeutic interventions. May also predict adverse responses to treatments.
Reproductive carrier
screening
Traditionally used to determine the carrier status of couples suspected to be at a higher risk of having a child with a recessive or
X-linked genetic condition. This has included individuals with an ethnic background known to have a greater prevalence of certain
genetic conditions (e.g., Tay-Sachs disease in the Ashkenazi Jewish population) (18), or based on family history (e.g., a family
member, including a previous child, with cystic fibrosis) (19).
Simultaneous “expanded” carrier screening for more than one recessive or X-linked condition has been facilitated through the use of
gene panels (20). In many countries it is possible for individuals or couples, including those with only average risk, to access these
tests through a user pays scenario.
When a couple is determined to be at greater risk of their future children having a genetic condition/s, their options include averting
the birth of an affected child by refraining from having children, PGD, prenatal diagnosis and subsequent termination of an affected
fetus, adoption or the use of donor gametes; preparation for the arrival of a child with a given condition; and the early
commencement of treatments or preventions to alleviate disease in an affected fetus/child.
Posthumous Molecular autopsies can occur on post-mortem tissue for sudden unexplained death (SUD), including in utero death. For example,
inherited arrhythmia syndromes identified through molecular diagnosis may be identified as the cause of death for some
autopsy-negative sudden unexpected death patients (21). For in utero deaths where other clinical signs were evident, or even those
that might have been predicted, posthumous testing can confirm a suspected diagnosis. Increasingly this is also being applied for
fetuses, stillbirths, and neonatal deaths with multiple congenital anomalies.
informed consent may differ depending on the life cycle stage and
purpose of the test (Table 2).
For example, the ethical issues surrounding diagnostic testing
are undoubtedly less contentious than those involved with
predictive testing of a living individual. In the first scenario a
patient has usually already presented to a healthcare professional
with symptomology, therefore the choice of the genomic
diagnostic test and subsequent data interpretation is simplified
and clinical utility usually aligns well with an individual’s
expectation of personal utility. This is true even if a treatment
or intervention is not available, as a molecular diagnosis can
end the diagnostic odyssey and potentially facilitate access to
applicable health and social services (32). Comparatively, it can
prove more complicated to predict the likelihood of a person
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TABLE 2 | The scope and challenges associated with genomic testing across different life cycle stages.
Considerations across the life cycle Life cycle stage
Reproductive age Preimplantation Prenatal Pediatric Adult Posthumous
SCOPE OF TEST
Who is primarily tested? Prospective parents Embryo Fetus/mother Child Adult Deceased
Who does the healthcare decision primarily
concern?
Prospective
parents/potential
embryos
Embryo Fetus/mother Child Adult Family members
Is a phenotype available at time of testing? No No Possibly Possibly Possibly Possibly
TYPE OF TESTS AVAILABLE
Screening X X X X X
Diagnostic X X X X X
Personal/direct-to-consumer
(non-clinical)/pharmacogenomics
X X
Microorganism X X X
Prognostic/Predictive/Presymptomatic X X X X
CONDITIONS IDENTIFIED
Inherited germline X X X X X X
Acquired germline X X X X X
Somatic X X X
PERSONAL AND CLINICAL UTILITY OF GENOMIC INFORMATION FOR TESTED INDIVIDUALS AND/OR FAMILY MEMBERS VIA CASCADE SCREENING
Reproductive choice (e.g., not having children,
assisted reproduction, termination)
X X X X X X
Preparation for future X X X X X X
Prevention or intervention X X X
Providing a molecular diagnosis (new or suspected) X X X X X
Inform treatment and/or management options X X X
POTENTIAL HEALTH CONSEQUENCES OF FALSE POSITIVES
Decision not to implant an unaffected embryo X
Termination of an unaffected fetus X
Unnecessary use of assisted reproductive
technology
X
Over diagnosis, over treatment, or wrong treatment X X X
Unnecessary cascade testing or cascade testing for
a wrongly attributed variant
X X X X X
POTENTIAL HEALTH CONSEQUENCES OF FALSE NEGATIVES
Missed opportunity for prior preparation, prevention,
or intervention
X X X X X X
No or wrong treatment X X X X
Missed opportunity for cascade testing for a
wrongly attributed variant
X X X X X
INFORMED CONSENT
Tested individual unable to consent X X X X
ASPECTS RELEVANT ACROSS THE LIFE CYCLE
Implications, considerations, and uses of test results Research translation, incidental or secondary findings, non-actionable findings, non-health related traits,
forensic investigation, ancestry, insurance, variants of unknown significance, sensitivity of data, longevity
of data, versatility of data, reference data, genomic literacy.
potentially developing a disease at some point in the future.
This is especially true for a person who has not yet been
born, such as when predicting risk of a disease for a current
(preimplantation or prenatal diagnosis) or future (preconception
carrier screening) embryo or fetus. The absence of familial
information such as in the case of adoption or gamete donation
can add more complexity. The potential implications of the
action/s taken based on genomic information in these situations
are also greater, due to the possibility of an embryo not being
selected for implantation, or the choice to terminate an affected
fetus (Table 2).
Despite the potential benefits associated with increasing
use of genomic testing, our knowledge of the relationship
between genomic variants and health is still evolving and
Frontiers in Public Health | www.frontiersin.org 4 March 2019 | Volume 7 | Article 40
Bilkey et al. Genomics Across the Life Cycle
is limited by the complex interactions between the genome
and other biological and environmental influences. Three key
considerations relating to this potential include the utility of
genomic testing for clinicians and the person, or patient; issues
around genomic data such as the sensitivity and potential
longevity of the data, data sharing and appropriateness of
the reference genome; and issues around informed consent
in the context of the complexity and expanding usage of
genomic testing. The issues that are explored below, while not
exhaustive, provide a broad overview of some of the challenges
and considerations of genomic testing across the life cycle.
Additional ethical, legal and social issues associated with genomic
testing, including challenges associated with direct-to-consumer
testing, are beyond the scope of this paper and are discussed
elsewhere (33, 34).
Utility
Personal and Clinical Uses for Genomic Information
Clinical utility for genomic testing is generally limited
to situations where genomic information directs and
improves patient care. Therefore, genomic testing may not
be recommended clinically if the results are unlikely to
impact care. However, genomic information has multiple
applications beyond the healthcare setting. For example,
individuals may wish to have their genome sequenced to
learn about their ancestry or non-health related traits; a
genomic diagnosis can inform eligibility for special education
and employment services; and genomic information is of
interest to insurance companies and can be used in forensic
settings. The manifold nature of genomic information
could allow for more efficient healthcare due to the
potential ability to reinterrogate data for multiple healthcare
purposes. However, the value of such data to individuals
and organizations beyond healthcare raises issues around
consumer expectations when clinical utility and other kinds of
utility diverge.
The utility of testing varies across the lifespan, potentially
in relation to when the testing is performed and for which
conditions the testing may relate (Table 2). In some settings
genomic information is used to make healthcare decisions
about an individual who may not have been able to provide
consent (e.g., prenatal screening or diagnosis; patients with
cognitive impairment). Furthermore, in particular settings
the test not only informs treatment and management, but
influences reproductive decisions which can be inherently more
personal (as opposed to clinically led), compared to other
healthcare decisions.
There are also limitations to the clinical utility of testing.
For example in the preconception setting, the genomic test can
only inform parents about risk of inherited conditions, and
cannot provide information about de novo or acquired genetic
conditions (Table 2). A particular consideration for the utility
of testing across the life cycle is the presence (or absence) of a
phenotype to aid clinical, as well as personal, decision-making.
Genomic data has the potential to identify disease risk earlier
than is possible through the use of clinical or physiological
symptoms alone, meaning that interventions can be enacted
more promptly. However, there is a conundrum presented
whereby presence of a genetic variant may not necessarily mean
that the disease will manifest (i.e., there is incomplete penetrance)
(35), or where a variant is variably expressed among individuals
and it is not possible to predict the severity based on genomic
information alone.
In such situations, clinicians would ideally draw upon the
presence of phenotype to aid in decision-making, and this
is absent in the preconception and preimplantation stages,
and often absent, or markedly limited, in the in utero setting
(Table 2). Likewise, the use of genomic testing for screening
includes the testing of asymptomatic individuals by definition,
and this can occur at any life stage (Table 2). Assurance of the
natural progression of genetic variants and the likelihood of
resulting disease is required for individuals to make reproductive
and healthcare choices. Similarly this information is needed for
clinicians to make clinical decisions, yet currently this knowledge
is limited. As a consequence, the clinical utility of genomic testing
for many conditions currently remains relatively low.
In some circumstances, genomic information may have
greater personal utility to patients compared to other medical
test results. Therefore, there may be times where personal utility
and clinical or healthcare utility are non-congruent. Available
evidence indicates that many consumers would only seek
genomic testing for actionable health information, particularly
in situations where there is a perceived need for that information
(4). However, certain subsets of the population may be more
receptive to receiving non-actionable genomic results, in which
case personal utility may override a lack of overt clinical
utility. Common situations where these benefits arise include
for parents of children with rare undiagnosed genetic diseases
(36), testing for the risk of late-onset conditions at a point
in the lifecycle where there is no clinical utility for such
information (37), and testing for risk of conditions with no
current treatments, such as Alzheimer’s disease predisposition
(38). Additional benefits cited for wanting to access testing
in these situations include ending the diagnostic odyssey, a
clearer understanding of the cause of a condition, greater
understanding of future needs, the ability to connect with
others in the same situation, and helping to gain access to
social and healthcare services (32, 38, 39). Personal utility of
a genomic test may also vary depending on a person’s cultural
background (40, 41).
In the era of personalized medicine and given that the
degree of personal utility is likely to vary between persons,
the utility of a genomic test is ultimately best estimated on
an individual basis (42). Empowering patients and families
to be involved in decisions will help to facilitate this (32).
However, individuals and healthcare providers should recognize
the inherent differences in value placed on genomic testing by
different stakeholders. Variation in perceptions of the utility
of genomic testing highlights the importance of accessible
and appropriate education and genetic counseling for anyone
considering a genomic test (43) (see Box 1). To enable
this, sufficient genomic literacy is required across the health
workforce to ensure health professionals are able to competently
counsel individuals and families (46, 47). This could be
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BOX 1 | Genetic counseling.
Genetic counseling has traditionally focused on the education and support for patients and family members who have, or are at risk of, Mendelian disorders (44).
With the increased integration of genomic testing in the healthcare system across the life cycle, the ability to provide adequate counseling to patients with the current
workforce and services model will be tested. The current workforce will be challenged to provide optimal counseling with increased demand, and new models
for delivering genetic counseling services may be required to fill this gap. New models could include bolstering the skills of the primary healthcare workforce (45),
increasing the use of evidence-based online delivery, and utilization of technology such as telehealth to mitigate hurdles such as geography for the rural and remote
population. Issues around genetic counseling for genomic tests are outlined in Burns et al. 2019 (46).
enabled through increased education and training of health
professionals (48).
Research and Translational Uses of Genomic Testing
Genomic testing may be used in situations where the primary
utility is to inform basic research or to identify eligibility for
treatments or services. For genetic conditions without well-
defined natural histories, for which there are few or no treatments
available (e.g., rare diseases, including rare cancers), or where
disease progression is rapid (e.g., advanced cancers), research and
translational uses of genomic testing may be crucial. There could
be a lack of knowledge or clinical consensus of the clinical utility
of genomic testing in such contexts (49), but there might still be
real or perceived utility for patients, clinicians, and researchers.
Due to the rarity of genetic conditions and the increasing utility
for genomic testing in treating cancer, management of these
particular patient cohorts relies heavily on basic research.
Consideration of these additional uses for genomic testing
in healthcare is important, particularly through the lens of
providing equitable healthcare to those who need it. Only 14%
of new scientific discoveries enter daily clinical practice, after an
average lag of 17 years (50). This lag is especially problematic for
(i) cancer patients, where disease prognosis can often be poor,
but for whom tailored treatment is showing promise, and (ii) for
patients with rare diseases for whom no, or limited pre-existing
treatment is available. In this context, translating the benefits
of genomic technology into the healthcare setting in a timely
manner is challenging (51). Multiple agencies at both the national
and international levels may be working on similar, smaller-scale
research projects. This could lead to inconsistent findings due
to sample size limitations, thereby becoming one of the rate-
limiting steps in the integration of genomic advances into daily
practice, and then into population-level programs. National and
international collaboration between researchers has the potential
to streamline this approach so that collective goals are expedited,
and translation into practice is accelerated (51–53).
An additional consideration around the lag in translation of
testing into the public healthcare setting is the potential for
individuals to have their genome sequenced in a non-clinical
setting (e.g., personal genomics) or a private healthcare setting,
which may create expectations for increased access in public
health systems. Genomic tests may be introduced first into
private (user pays) settings due to the initially high cost and
the lag in translation into public health systems, which must
balance investment into multiple different aspects of healthcare
(54), and as a result, often have a high evidence threshold for
integrating new tests into practice. This can increase demand for,
and produce inequity of access to, testing that may be beneficial
for improving healthcare, but which health systems are not yet
prepared to offer at a population-wide level (55).
Incidental or Secondary Findings
Genomic data can be interrogated in different ways, including
broad approaches designed to capture as much information as
possible and targeted approaches focused on a few variants of
interest. Incidental or secondary findings are classified as gene
variants that are not the primary focus of a specific genomic
test and are not necessarily related to the condition/s being
investigated [e.g., (56)]. These variants can be obtained when
performing whole genome and exome sequencing, as well as
with certain gene panels, and if scrutinized, may reveal the
need to consider medical action. There have been efforts to
identify a minimum list of variants that are considered medically
actionable. The American College of Medical Genetics and
Genomics has developed a widely used list of 59 genes to be
reported in clinical settings as incidental or secondary findings
(57). Incidental findings relating to germline variants and familial
relationships are relevant across the life cycle (Table 2). A
particular point of difference is the use of non-invasive prenatal
testing, in which fetal DNA and maternal DNA can be identified
in the same sample, which may reveal incidental findings relating
to somatic changes present in the mother.
There is variation among consumers, pathologists, specialists,
researchers and professional societies regarding the need to
return incidental findings to patients, with the definition of
incidental often being dependent on the medical specialty or
setting (58, 59). Consumers may consider that raw data or
medically significant incidental findings should be accessible to
them even when their genome is sequenced for a non-clinical
purpose (60, 61). This raises important legal issues surrounding
the right to access personal information (43, 60), particularly
when incidental findings relate to potentially actionable variants
(62). However, there may be issues in the clinical utility
of such information given the different requirements for
sequencing quality in non-clinical settings (60, 63). Managing
consumer/patient expectations is therefore of critical importance.
A dialogue involving all stakeholders, including the patient
or consumer, may be required to agree on a set of criteria that
could indicate when incidental findings should or should not
be returned to individuals (64). A relevant question is whether
researchers and genomics laboratories should be returning raw
data or incidental findings given that many patients access
genomic testing through research projects or directly from
laboratories. Recent changes to the National Health and Medical
Research Council’s National Statement for Ethical Conduct
in Human Research, with which researchers must comply,
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require a system to be in place to return findings that have
health significance to participants (65). Other relevant questions
include, will guidelines and regulations around incidental
findings influence clinicians in ordering gene-specific analyses
rather than clinical genomes or exomes? What is the likely effect
of this on the utility of the test?
Variants of Uncertain Significance
By definition, variants of uncertain significance (VUS) have
unknown clinical utility (66). It is understood that as knowledge
of genomic variants and the relationship between variants and
disease pathology advances, variants that have previously been
identified as uncertain may be recognized as pathogenic, or
alternatively benign. Internationally, guidelines surrounding the
responsibility to report VUS are a work in progress. Variant
interpretation, even in the setting of a clear phenotype, can
be challenging at both the individual and health system levels.
The medico-legal implications of variants at one point in
time being identified as uncertain, and then with advances in
knowledge being later identified as pathogenic, are highlighted
in the law case of Williams vs. Athena (see Box 2). Significant
questions include where do we draw the line on requirements
to report based on knowledge of pathogenicity? How frequently
should reference databases be updated and consulted to inform
contemporary interpretation of results? Do patients wish to know
about VUS if they are found? Is there an obligation to follow up
VUS after the test has been taken, in accordance with changes in
classification as knowledge develops? If so, who is responsible for
doing this?
Genomic Data
Genomic data are becoming increasingly useful not only for
understanding the causes of ill health, but also the genomic
determinants of good health. However, there are ethical, legal,
and social issues that need to be considered to ensure appropriate
use of genomic data in healthcare. These include that genomic
information is not only personal, but also familial (i.e., it can
reveal familial relationships and personal information about
relatives); that the longevity, particularly of germline genomic
data, exceeds that of typical health information; that the
broad utility of genomic data increases the demand for data
sharing; and that equitable genomic testing relies on appropriate
reference data.
Sensitivity of Genomic Data
The collection and generation of genomic information comes
with some unique ethical issues. The security and privacy
of genomic information challenges traditional paradigms of
confidentiality for sensitive information, given that a person’s
genomic information can be compared to a fingerprint, such that
it can never be truly de-identified. Genomic information may
therefore require additional regulation, such as the addition of
noise to the data to ensure protection of privacy (67, 68).
Genomic data can impact biologically related family members
even if they have not accessed genomic testing themselves. With
the possibility for on-sharing of genomic information for future
uses other than the intended purpose of the initial test, concerns
over the privacy of genomic data and issues of informed consent
for the disclosure and use of genomic information become
paramount. Recently this was illustrated in California, where
police used genomic information from an open source database
from genealogy company GED match to facilitate the arrest of a
serial rapist and murderer known as “The Golden State Killer”
(69). The suspect, who is accused of committing crimes more
than 3 decades ago, did not himself have genomic information
in the database, but rather one of his relatives had participated.
Longevity of Genomic Data
Germline genomic data is somewhat unique in its unchanging
nature, meaning that the same data could be reinterrogated
over the life cycle for different health and non-health related
purposes. The potential of genomic information is therefore
longer lasting in contrast to many other types of health test
results, which may provide more of a health snapshot. This
makes genomic information more similar to stored biological
samples collected in biobanks. Future innovations will allow for
improved interrogation of historical genomic data (3, 70). In the
inevitable advent of improved interrogation ability, is it ethical to
analyse existing, historical datasets with improved technologies,
and contrastingly, is it ethical to omit reinterrogation of existing
datasets with new technologies (71)? Future tools for analysis
and enhanced genomic knowledge may alter an individual’s risk
profile with reinterrogation of existing data (72). With increasing
applications in precision medicine and precision public health,
disease risk could become dynamically updated depending on
current knowledge and data. The potential for rapid change in
technology should be considered when determining how long to
store genomic data. Careful management of consumer or patient
expectations should also be considered.
The integration of genomic testing that is currently occurring
separately across the life cycle may facilitate greater efficiencies in
healthcare, but would require coordination and communication
among previously isolated healthcare settings. With the
increasing application of genomic testing across the life cycle, the
potential to use one test for multiple purposes is increasing (73).
For example, if genomic testing is introduced at a population
level in more than one setting, the possible number of individual
tests taken over the lifespan for a single individual is likely to
increase. Assuming there is agreed utility for each type of testing
at a population level, would broad sequencing such as whole
genome or whole exome sequencing and long-term storage of
genomic test results ultimately become more cost effective than
repeat testing?
What if every baby’s exome or genome was sequenced and
reanalyzed as needed for different purposes throughout their life,
would the cost savings from a reduced need to re-test outweigh
the cost of storing the relevant data? A single genomic test could
provide the answer to a patient’s symptomatology that would
have otherwise required multiple tests (74), and may also provide
information relevant for different healthcare decisions in that
person’s life (Table 2). However, it may also lead to a short-
term increase in healthcare demand from different healthcare
professionals. For example, an actionable secondary finding
may mobilize cascade screening in family members that would
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BOX 2 | Case study-Legal issues in variant interpretation.
A case study which highlights potential legal issues surrounding variant interpretation is the current USA lawsuit,Williams vs. Athena, where a 2 year old boy, Christian
Jacob Millare, died of a fatal seizure from Dravet syndrome in January 2008. In 2007, Christian was tested for Dravet syndrome, and the report concluded that he
had a “variant of unknown significance,” and as such Christian continued to be treated as if he had a mitochondrial disorder rather than Dravet syndrome. In 2015,
the laboratory responsible for the test, Athena, updated its report to reclassify the mutation as pathogenic for Dravet syndrome, as Christian was found to have a
pathogenic variant in the SCN1A gene. Interestingly at the time of the initial report, there were two publications (published in 2006 and 2007) each based on another
single case reporting the same variant that Christian had as being pathogenic. Inherent to this case were the issues of whether a laboratory classifies as a health
service provider, and relatedly the communication and responsibilities of laboratories and physicians. The case also emphasized the need for stricter governance
around how variant databases report and interpret their data (6).
otherwise not have occurred (53), or may indicate consideration
of alternative reproductive choices for individuals in the family.
In addition, such long term storage and reinterrogation of
genomic data would require processes for obtaining consent
for each subsequent analysis over a long time period. The
implications of broad sequencing methods and use of genomic
data should be carefully examined prior to any large-scale
implementation (75).
The potential for integration of genomic testing across
the life cycle will not be without challenges. In such a
context it is important to determine who is responsible
for reporting results; which results should be reported and
when; and whether to store and reanalyse results at a later
time. The complexities of healthcare systems and governance
arrangements across responsible organizations create the
need for a harmonized approach at the local, national and
international levels.
Data Sharing and Regulation
The benefits to be obtained from the use of genomic technology
in healthcare are reliant on global cooperation and data sharing
(2, 76). This is particularly the case for rare genetic conditions,
where sharing of patient data can be critical to achieving
a diagnosis or conducting research to improve healthcare.
Adequate governance and regulation is required to ensure that
genomic data are used responsibly by those who are permitted
access. In 1997, the United Nations Educational, Scientific and
Cultural Organization developed a Universal Declaration on the
Human Genome and Human Rights, and, in 2003, adopted an
International Declaration on Human Genetic Data to guide the
use of such data at an international level (77).
Internationally, the regulatory space continues to evolve.
The United States of America (USA) has developed regulations
and legislation governing the protection and use of genetic
information. The Genetic Information Nondiscrimination Act of
2008 protects the genetic privacy of individuals by preventing
insurers or employers from requesting genetic information.
However, a bill for the Preserving Employee Wellness Programs
Act has been introduced to the USA Senate, and has the potential
to jeopardize present legislation protecting individuals from
their employers requesting disclosure of genetic information
and imposing penalties for non-disclosure (35). In Canada,
the Genetic Non-Discrimination Act prohibits a person from
requiring an individual to disclose their genetic information as a
condition of providing goods or services to that individual, with
exceptions for healthcare practitioners and researchers.
The requirements for responsible use of genomic information
are similar to those for other health-related and personal
information. The European Union (EU) has developed a General
Data Protection Regulation that applies to businesses that
process or control data from within the EU. Discrimination
against individuals on the basis of their genetic information
is also banned in Europe in accordance with the Council of
Europe’s Oviedo Convention. These regulations are important
to ensure that data can be shared responsibly and ethically,
which will encourage individuals to continue to participate in
health research.
Reference Data
The importance of reference genomes in utilizing genomic
testing is reliant on large-scale data sharing and collaboration.
Reference genomes are used for comparison purposes, as a
representative example of a typical human’s genome sequence.
These genomes are developed using a mosaic of genetic
information sourced from different individuals and combined
to form a template sequence. The use of reference genomes in
utilizing genomic technology raises concerns around offering
genomic testing that is less effective in some ethnicities compared
to others, since genetic disease risk varies among ethnicities
(78, 79). However, the use of an appropriate reference genome
is made more difficult by the increasing multiculturalism
within countries.
For equitable understanding of genomic variants, reference
databases must be capable of reflecting the ethnic diversity
of the relevant population/s, such as minority groups and/or
Indigenous populations (80). It has been highlighted that most
genomic reference databases do not adequately reflect the
diversity of human populations (7). As an example, the cultural
makeup of Australia’s population is highly diverse, including
Aboriginal and Torres Strait Islander peoples, and having a
higher proportion of people born overseas compared to the
USA, New Zealand, and Canada (81). However, there is a
paucity of genetic data available for Aboriginal and Torres
Strait Islander peoples, such that interpretation of genetic
variants currently needs to be addressed with caution (82). For
multicultural societies, it is vital to ensure that minority ethnic
populations are not disadvantaged in accessing the benefits of
genomic technology.
Informed Consent
Informed consent for genomic testing in healthcare is complex
when we try to consider all of the issues outlined above,
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including the variety of different testing methods and potential
to test for multiple conditions at once; the testing of non-
consenting individuals; potential for reinterrogation or sharing
of data; the lack of diagnostic certainty in particular test settings;
the complexities surrounding interpretation of tests, VUS and
incidental findings; implications for insurance and other services;
and the potential impact of testing on family members. Some of
these issues are more pertinent in particular test settings across
the life cycle (Table 2).
For example, the current guidelines on prenatal testing from
the Royal Australian and New Zealand College of Obstetricians
and Gynaeocologists state that information provided to women
should include descriptions of conditions to be tested, as well as
information about both the variance in phenotype and ability to
predict the conditions tested (83). In the context of increasing
lists of conditions to be screened for through the use of expanded
genetic testing panels or whole exome/genome sequencing, how
can healthcare providers ensure that the decision to undergo such
testing is adequately informed?
The complexity of ethical, legal, and social issues surrounding
consent for genomic testing indicate that substantial effort
is required to ensure adequate understanding of the test by
consumers. Depending on how many of these issues apply,
professional genetic counselingmay be critical for obtaining truly
informed consent for genomic tests. Informed consent should be
obtained based on the individual’s circumstances to the extent
that this is possible. Patient decision aids may be helpful for
achieving this approach, particularly for applications where for
some people the personal benefits outweigh the lack of clinical
utility (84, 85). Such tools have been developed to help parents
decide whether to undergo screening for Down syndrome (86),
and to support reproductive decision-making for individuals
with a genetic predisposition to heritable cancer (87). Decision
aids may need to be tailored to the level of health literacy of
users (88).
Consideration must also be given to a model where informed
consent to personal genomic data analysis and storage can
allow for the possibility that data may be reviewed, and thus
for the possibility that an individual or their family might be
contacted in relation to the updated outcomes in the future if
this occurs (89). In the context of including late-onset conditions
in tests performed on fetuses or children, is there a moral
obligation to ensure this information can be communicated
to individuals once they reach the age of informed consent?
Dynamic consent models in this instance are one such example
of a flexible, digitally-enabled consent model that may cater
more broadly to the needs of healthcare consumers (8). Evidence
so far shows that healthcare consumers want ownership and
control over their health data (90, 91). Several companies
are developing applications to allow greater access to, and
control of, genomic information by consumers (e.g., Helix
online genomics marketplace; Seqster platform). Much of this
development is currently occurring in the personal genomics
space, but similar efforts are being made in public health systems
in association with moves to electronic health records. This
patient-centered approach will be increasingly important with
the rise in personalized medicine and precision public health, but
will need to be implemented in a considered and ethical manner.
CONCLUSIONS
Genomic technologies challenge aspects of traditional healthcare
delivery, with new ethical issues arising from these unchartered
waters. The increasing utilization of genomic testing across
different healthcare settings over the life cycle necessitates
increased clarity of purpose and raises important ethical, legal,
and social issues. Healthcare providers will be required to
adopt an approach to genomic technology that will allow for
the advancement of genomic knowledge and the responsible
application of technology to benefit the population across the
life cycle. In the context of the complexity and versatility of
genomic information and its inherently personal and familial
nature, adequate governance and informed consent are critical
considerations for implementing genomic testing for healthcare.
AUTHOR CONTRIBUTIONS
TW, HD, and GAB conceived the paper concept. BB, GAB, EC,
and KN drafted the manuscript. All authors provided critical
input and approved submission of the final manuscript.
FUNDING
In-kind support was provided through the Western Australian
Department of Health.
REFERENCES
1. Williamson R, AndersonW,Duckett S, Frazer I, Hillyard C, Kowal E, et al.The
Future of PrecisionMedicine in Australia. Melbourne, VIC: Australian Council
of Learned Academies (2018).
2. Rehm HL. Evolving health care through personal genomics. Nat Rev Genet.
(2017) 18:259. doi: 10.1038/nrg.2016.162
3. Gaff CL, Winship IM, Forrest SM, Hansen DP, Clark J, Waring PM, et al.
Preparing for genomic medicine: a real world demonstration of health system
change. NPJ Genomic Med. (2017) 2:16. doi: 10.1038/s41525-017-0017-4
4. Metcalfe SA, Hickerton C, Savard J, Terrill B, Turbitt E, Gaff C,
et al. Australians’ views on personal genomic testing: focus group
findings from the Genioz study. Eur J Human Genet. (2018) 26:1101–12.
doi: 10.1038/s41431-018-0151-1
5. Turbitt E, Wiest MM, Halliday JL, Amor DJ, Metcalfe SA. Availability
of treatment drives decisions of genetic health professionals about
disclosure of incidental findings. Eur J Human Genet. (2014) 22:1225.
doi: 10.1038/ejhg.2014.11
6. Thorogood A, Cook-Deegan R, Knoppers BM. Public variant databases:
liability? Genet Med. (2017) 19:838–41. doi: 10.1038/gim.2016.189
7. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. (2016)
538:161. doi: 10.1038/538161a
8. Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic
consent: a patient interface for twenty-first century research networks. Eur J
Human Genet. (2015) 23:141. doi: 10.1038/ejhg.2014.71
9. Cookson W, Cox MJ, Moffatt MF. New opportunities for managing
acute and chronic lung infections. Nat Rev Microbiol. (2017) 16:111–20.
doi: 10.1038/nrmicro.2017.122
Frontiers in Public Health | www.frontiersin.org 9 March 2019 | Volume 7 | Article 40
Bilkey et al. Genomics Across the Life Cycle
10. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al.
Gut microbiome influences efficacy of PD-1-based immunotherapy against
epithelial tumors. Science. (2017) 359:91–7. doi: 10.1126/science.aan3706
11. Grice EA, Segre JA. The human microbiome: our second
genome. Ann Rev Genomics Human Genet. (2012) 13:151–70.
doi: 10.1146/annurev-genom-090711-163814
12. Jansen ME, Metternick-Jones SC, Lister KJ. International differences in
the evaluation of conditions for newborn bloodspot screening: a review of
scientific literature and policy documents. Eur J Human Genet. (2017) 25:10.
doi: 10.1038/ejhg.2016.126
13. Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-consumer testing
2.0: emerging models of direct-to-consumer genetic testing.Mayo Clinic Proc.
(2018) 93:113–20. doi: 10.1016/j.mayocp.2017.11.001
14. Chen M, Wei S, Hu J, Quan S. Can comprehensive chromosome screening
technology improve IVF/ICSI outcomes? A meta-analysis. PloS One. (2015)
10:e0140779. doi: 10.1371/journal.pone.0140779
15. Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman OA,
Madan J, et al. Accuracy of non-invasive prenatal testing using cell-
free DNA for detection of Down, Edwards and Patau syndromes:
a systematic review and meta-analysis. BMJ Open. (2016) 6:e010002.
doi: 10.1136/bmjopen-2015-010002
16. Dickinson JE. Noninvasive prenatal testing: known knowns and known
unknowns. Aust N Z J Obst Gynaecol. (2014) 54:397–9. doi: 10.1111/ajo.12269
17. Woolcock J, Grivell R. Noninvasive prenatal testing. Aust Family Phys.
(2014) 43:432–4.
18. Lew RM, Burnett L, Proos AL, Delatycki MB. Tay-Sachs disease:
current perspectives from Australia. Appl Clin Genet. (2015) 8:19–25.
doi: 10.2147/TACG.S49628
19. Massie J, Delatycki MB. Cystic fibrosis carrier screening. Paediatr Respir Rev.
(2013) 14:270–5. doi: 10.1016/j.prrv.2012.12.002
20. Edwards JG, Feldman G, Goldberg J, Gregg AR, Norton ME, Rose NC,
et al. Expanded carrier screening in reproductive medicine—points to
consider: a joint statement of the American College of Medical Genetics
and Genomics, American College of Obstetricians and Gynecologists,
National Society of Genetic Counselors, Perinatal Quality Foundation, and
Society for Maternal-Fetal Medicine. Obst Gynecol. (2015) 125:653–62.
doi: 10.1097/AOG.0000000000000666
21. Dewar LJ, Alcaide M, Fornika D, D’Amato L, Shafaatalab S, Stevens CM,
et al. Investigating the genetic causes of sudden unexpected death in children
through targeted next-generation sequencing analysis. Circ Cardiovasc Genet.
(2017) 10:e001738. doi: 10.1161/CIRCGENETICS.116.001738
22. Lionel AC, Costain G, Monfared N, Walker S, Reuter MS, Hosseini SM, et al.
Improved diagnostic yield compared with targeted gene sequencing panels
suggests a role for whole-genome sequencing as a first-tier genetic test. Genet
Med. (2017) 20:435–43. doi: 10.1038/gim.2017.119
23. Watson CM, Camm N, Crinnion LA, Clokie S, Robinson RL, Adlard J,
et al. Increased sensitivity of diagnostic mutation detection by re-analysis
incorporating local reassembly of sequence reads. Mol Diagn Ther. (2017)
21:685–92. doi: 10.1007/s40291-017-0304-x.
24. Gambin T, Akdemir ZC, Yuan B, Gu S, Chiang T, Carvalho CMB, et al.
Homozygous and hemizygous CNV detection from exome sequencing
data in a Mendelian disease cohort. Nucleic Acids Res. (2017) 45:1633–48.
doi: 10.1093/nar/gkw1237
25. Schneider H, Faschingbauer F, Schuepbach-Mallepell S, Körber I, Wohlfart
S, Dick A, et al. Prenatal correction of X-linked hypohidrotic ectodermal
dysplasia. N Engl J Med. (2018) 378:1604–10. doi: 10.1056/NEJMoa17
14322
26. Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al.
Liquid biopsies come of age: towards implementation of circulating tumour
DNA. Nat Rev Cancer. (2017) 17:223. doi: 10.1038/nrc.2017.7
27. Lu T, Li J. Clinical applications of urinary cell-free DNA in cancer: current
insights and promising future. Am J Cancer Res. (2017) 7:2318–32.
28. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson
R, et al. Implementing genomicmedicine in the clinic: the future is here.Genet
Med. (2013) 15:258. doi: 10.1038/gim.2012.157
29. Green ED, GuyerMS. Charting a course for genomicmedicine from base pairs
to bedside. Nature. (2011) 470:204. doi: 10.1038/nature09764
30. Khoury MJ, Ioannidis JPA. Big data meets public health: human well-being
could benefit from large-scale data if large-scale noise is minimized. Science.
(2014) 346:1054–5. doi: 10.1126/science.aaa2709
31. PHG Foundation. Public Health in an Era of Genome-Based and Personalised
Medicine. Cambridge: PHG Foundation (2010).
32. Brosco JP. Whose odyssey is it? Family-centered care in the genomic era.
Hastings Cent Rep. (2018) 48:S20–2. doi: 10.1002/hast.879
33. Molster CM, Bowman FL, Bilkey GA, Cho AS, Burns BL, Nowak KJ, et al. The
evolution of public health genomics: exploring its past, present, and future.
Front Public Health. (2018) 6:247.doi: 10.3389/fpubh.2018.00247
34. Rafiq M, Ianuale C, Ricciardi W, Boccia S. Direct-to-consumer genetic
testing: a systematic review of european guidelines, recommendations,
and position statements. Genet Testing Mol Biomark. (2015) 19:535–47.
doi: 10.1089/gtmb.2015.0051
35. Bilkey GA, Baynam G, Molster C. Changes to the employers’ use of
genetic information and non-discrimination for health insurance in the
USA: implications for Australians. Front Public Health. (2018) 6:183.
doi: 10.3389/fpubh.2018.00183
36. Sapp JC, Dong D, Stark C, Ivey LE, Hooker G, Biesecker LG, et al. Parental
attitudes, values, and beliefs toward the return of results from exome
sequencing in children. Clini Genet. (2014) 85:120–6. doi: 10.1111/cge.12254
37. Goldenberg AJ, Sharp RR. The ethical hazards and programmatic
challenges of genomic newborn screening. JAMA. (2012) 307:461–2.
doi: 10.1001/jama.2012.68
38. Lim Q, McGill BC, Quinn VF, Tucker KM, Mizrahi D, Farkas Patenaude A,
et al. Parents’ attitudes toward genetic testing of children for health conditions:
a systematic review. Clini Genet. (2017) 92:569–78. doi: 10.1111/cge.12989
39. Gogarty B. Parents as Partners: A Report and Guidelines on the Investigation of
Children with Developmental Delay; by Parents, for Professionals. Cambridge:
Cambridge Genetics Knowledge Park (2006).
40. Haidar H, Vanstone M, Laberge A-M, Bibeau G, Ghulmiyyah L, Ravitsky
V. Cross-cultural perspectives on decision making regarding noninvasive
prenatal testing: a comparative study of Lebanon and Quebec.AJOB Empirical
Bioethics. (2018) 9:99–111. doi: 10.1080/23294515.2018.1469551
41. Amendola LM, Berg JS, Horowitz CR, Angelo F, Bensen JT, Biesecker BB, et al.
The clinical sequencing evidence-generating research consortium: integrating
genomic sequencing in diverse and medically underserved populations. Am J
Human Genet. (2018) 103:319–27. doi: 10.1016/j.ajhg.2018.08.007
42. Foster MW, Mulvihill JJ, Sharp RR. Evaluating the utility of personal genomic
information. Genet Med. (2009) 11:570. doi: 10.1097/GIM.0b013e3181a2743e
43. Middleton A, Mendes Á, Benjamin CM, Howard HC. Direct-to-consumer
genetic testing: where and how does genetic counseling fit? Personal Med.
(2017) 14:249–57. doi: 10.2217/pme-2017-0001
44. Kurti L, Tomiczek C, Brophy E, Fase D.The Changing Landscape of the Genetic
Counselling Workforce: Final Report. NSW: Urbis (2017).
45. Robins R, Metcalfe S. Integrating genetics as practices of primary care. Soc Sci
Med. (2004) 59:223–33. doi: 10.1016/j.socscimed.2003.10.025
46. Burns BL, Bilkey GA, Coles EP, Bowman FL, Beilby JP, Pachter NS, et al.
Healthcare system priorities for successful integration of genomics: an
Australian focus. Front Public Health. (2019) doi: 10.3389/fpubh.2019.00041
47. Marzuillo C, De Vito C, Boccia S, D’Addario M, D’Andrea E, Santini P,
et al. Knowledge, attitudes and behavior of physicians regarding predictive
genetic tests for breast and colorectal cancer. Prevent Med. (2013) 57:477–82.
doi: 10.1016/j.ypmed.2013.06.022
48. Ricciardi W, Boccia S. New challenges of public health: bringing the future
of personalised healthcare into focus. Eur J Public Health. (2017) 27:36–9.
doi: 10.1093/eurpub/ckx164
49. Khoury M, Berg A, Coates R, Evans J, Teutsch S, Bradley L. The
evidence dilemma in genomic medicine. Health Affairs. (2008) 27:1600–11.
doi: 10.1377/hlthaff.27.6.1600
50. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question:
understanding time lags in translational research. J Royal Soc Med. (2011)
104:510–20. doi: 10.1258/jrsm.2011.110180
51. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L.
The continuum of translation research in genomic medicine: how can
we accelerate the appropriate integration of human genome discoveries
into health care and disease prevention? Genet Med. (2007) 9:665.
doi: 10.1097/GIM.0b013e31815699d0
52. Manolio TA, Abramowicz M, Al-Mulla F, Anderson W, Balling R, Berger AC,
et al. Global implementation of genomicmedicine: we are not alone. Sci Transl
Med. (2015) 7:290ps13-ps13. doi: 10.1126/scitranslmed.aab0194
53. Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg
JS, et al. Clinical sequencing exploratory research consortium: accelerating
Frontiers in Public Health | www.frontiersin.org 10 March 2019 | Volume 7 | Article 40
Bilkey et al. Genomics Across the Life Cycle
evidence-based practice of genomic medicine. Am J Human Genet. (2016)
98:1051–66. doi: 10.1016/j.ajhg.2016.04.011
54. Tiller J, Lacaze P. Regulation of internet-based genetic testing: challenges
for Australia and other jurisdictions. Front Public Health. (2018) 6:24.
doi: 10.3389/fpubh.2018.00024
55. Khoury MJ, Feero WG, Reyes M, Citrin T, Freedman A, Leonard D, et al. The
genomic applications in practice and prevention network. Genet Med. (2009)
11:488. doi: 10.1097/GIM.0b013e3181a551cc
56. Middleton A, Morley KI, Bragin E, Firth HV, Hurles ME, Wright CF, et al.
Attitudes of nearly 7000 health professionals, genomic researchers and publics
toward the return of incidental results from sequencing research. Eur J Human
Genet. EJHG. (2016) 24:21–9. doi: 10.1038/ejhg.2015.58
57. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al.
Recommendations for reporting of secondary findings in clinical exome and
genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the
American College of Medical Genetics and Genomics. Genet Med. (2017)
19:249–55. doi: 10.1038/gim.2016.190
58. Turbitt E, Halliday JL, Metcalfe SA. Key informants’ perspectives of
implementing chromosomal microarrays into clinical practice in Australia.
Twin Res Human Genet. (2013) 16:833–9. doi: 10.1017/thg.2013.43
59. Christensen KD, Vassy JL, Jamal L, Lehmann LS, SlashinskiMJ, Perry DL, et al.
Are physicians prepared for whole genome sequencing? A qualitative analysis.
Clini Genet. (2016) 89:228–34. doi: 10.1111/cge.12626
60. Kaye J, Kanellopoulou N, Hawkins N, Gowans H, Curren L, Melham K. Can
I access my personal genome? The current legal position in the UK.Med Law
Rev. (2013) 22:64–86. doi: 10.1093/medlaw/fwt027
61. Middleton A, Wright CF, Morley KI, Bragin E, Firth HV, Hurles ME, et al.
Potential research participants support the return of raw sequence data. J Med
Genet. (2015) 52:571–4. doi: 10.1136/jmedgenet-2015-103119
62. Pike ER, Rothenberg KH, Berkman BE. Finding fault? Exploring legal
duties to return incidental findings in genomic research. Georgetown Law J.
(2014) 102:795–843.
63. Wolf SM, Lawrenz FP, Nelson CA, Kahn JP, Cho MK, Clayton EW,
et al. Managing incidental findings in human subjects research:
analysis and recommendations. J Law Med Ethics. (2008) 36:219–48.
doi: 10.1111/j.1748-720X.2008.00266.xt
64. Borry P, Bentzen HB, Budin-Ljosne I, Cornel MC, Howard HC, Feeney
O, et al. The challenges of the expanded availability of genomic
information: an agenda-setting paper. J Comm Genet. (2017) 9:103–16.
doi: 10.1007/s12687-017-0331-7
65. Eckstein L, Chalmers D, Critchley C, Jeanneret R, McWhirter R, Nielsen J,
et al. Australia: regulating genomic data sharing to promote public trust.
Human Genet. (2018) 137:583–91. doi: 10.1007/s00439-018-1914-z
66. Cheon JY, Mozersky J, Cook-Deegan R. Variants of uncertain significance in
BRCA: a harbinger of ethical and policy issues to come? Genome Med. (2014)
6:121. doi: 10.1186/s13073-014-0121-3
67. Lin Z, Owen AB, Altman RB. Genomic research and human subject privacy.
Science. (2004) 305:183. doi: 10.1126/science.1095019
68. Kahn SD. On the future of genomic data. Science. (2011) 331:728–9.
doi: 10.1126/science.1197891
69. Stanton S, Lillis R. Relative’s DNA from genealogy websites cracked
East Area Rapist case, DA’s office says. The Sacramento Bee (2018).
Available online at: https://www.sacbee.com/latest-news/article209913514.
html (Accessed September 7, 2018).
70. Bowdin S, Gilbert A, Bedoukian E, Carew C, Adam MP, Belmont J, et al.
Recommendations for the integration of genomics into clinical practice.Genet
Med. (2016) 18:1075. doi: 10.1038/gim.2016.17
71. Hall AE, Chowdhury S, Hallowell N, Pashayan N, Dent T, Pharoah P, et al.
Implementing risk-stratified screening for common cancers: a review of
potential ethical, legal and social issues. J Public Health. (2014) 36:285–91.
doi: 10.1093/pubmed/fdt078
72. Wenger AM, Guturu H, Bernstein JA, Bejerano G. Systematic reanalysis of
clinical exome data yields additional diagnoses: implications for providers.
Genet Med. (2017) 19:209. doi: 10.1038/gim.2016.88
73. Khoury MJ, Feero WG, Chambers DA, Brody LE, Aziz N, Green RC,
et al. A collaborative translational research framework for evaluating and
implementing the appropriate use of human genome sequencing to improve
health. PLoS Med. (2018) 15:e1002631. doi: 10.1371/journal.pmed.1002631
74. Science and Technology Committee. Genomics and Genome Editing in the
NHS. House of Commons (2018).
75. Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA.
Sequencing newborns: a call for nuanced use of genomic technologies.
Hastings Cent Rep. (2018) 48:S2–6. doi: 10.1002/hast.874
76. Middleton A. Society and personal genome data. Human Mol Genet. (2018)
27:R8–13. doi: 10.1093/hmg/ddy084
77. The UNESCO Universal Declaration on Bioethics and Human Rights:
Background, Principles and Application. UNESCO Publishing (2009).
78. Landry LG, Rehm HL. Association of racial/ethnic categories with the ability
of genetic tests to detect a cause of cardiomyopathy. JAMA Cardiol. (2018)
3:341–5. doi: 10.1001/jamacardio.2017.5333
79. Mak ACY, White MJ, Eckalbar WL, Szpiech ZA, Oh SS, Pino-Yanes M, et al.
Whole genome sequencing of pharmacogenetic drug response in racially
diverse children with asthma. Am J Respir Crit Care Med. (2018) 197:1552–64.
doi: 10.1164/rccm.201712-2529OC
80. Robertson S, Hindmarsh J, Berry S, Cameron V, Cox M, Dewes O, et al.
Genomic medicine must reduce, not compound, health inequities: the case
for hauora-enhancing genomic resources for New Zealand. N Zeal Med J.
(2018) 131:81–9.
81. Australian Bureau of Statistics. Cultural Diversity in Australia, 2016.
Canberra (2017).
82. Nowak KJ, Bauskis A, Dawkins HJ, Baynam G. Incidental inequity. Eur J
Human Genet. 26:616–7. doi: 10.1038/s41431-018-0101-y
83. The Royal Australian and New Zealand College of Obstetricians and
Gynaecologists and Human Genetics Society of Australia. Prenatal Screening
and Diagnosis of Chromosomal and Genetic Conditions in the Fetus in
Pregnancy. Melbourne, VIC: Royal Australian and New Zealand College of
Obstetricians and Gynaecologists and Human Genetics Society of Australia
(2015).
84. Barry MJ, Edgman-Levitan S. Shared decision making — The
pinnacle of patient-centered care. N Engl J Med. (2012) 366:780–1.
doi: 10.1056/NEJMp1109283
85. O’Connor AM,Wennberg JE, Legare F, Llewellyn-Thomas HA, Moulton BW,
Sepucha KR, et al. Toward the ‘tipping point’: decision aids and informed
patient choice. Health Affairs. (2007) 26:716–25. doi: 10.1377/hlthaff.26.3.716
86. Agbadjé TT, Menear M, Dugas M, Gagnon M-P, Rahimi SA, Robitaille H,
et al. Pregnant women’s views on how to promote the use of a decision
aid for Down syndrome prenatal screening: a theory-informed qualitative
study. BMC Health Services Res. (2018) 18:434. doi: 10.1186/s12913-018-
3244-1
87. Reumkens K, Tummers MH, Gietel-Habets JJ, van Kuijk SM, Aalfs CM, van
Asperen CJ, et al. The development of an online decision aid to support
persons having a genetic predisposition to cancer and their partners during
reproductive decision-making: a usability and pilot study. Familial Cancer.
(2019) 18:137–46. doi: 10.1007/s10689-018-0092-4
88. McCaffery KJ, Holmes-Rovner M, Smith SK, Rovner D, Nutbeam D, Clayman
ML, et al. Addressing health literacy in patient decision aids. BMC Med
Informat Dec Making. (2013) 13:S10. doi: 10.1186/1472-6947-13-S2-S10
89. Cameron L, Burton H. Genetic Screening Programmes: An International
Review of Assessment Criteria. Cambridge: PHG Foundation (2014).
90. Krohn R. The consumer-centric personal health record—it’s time. J Healthcare
Informat Management. (2007) 21:20–3.
91. Consumers Health Forum of Australia and NPS MedicineWise. Engaging
Consumers in their Health Data Journey. Canberra, ACT: CHF and NPS
MedicineWise (2018).
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Bilkey, Burns, Coles, Bowman, Beilby, Pachter, Baynam, Dawkins,
Nowak andWeeramanthri. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Public Health | www.frontiersin.org 11 March 2019 | Volume 7 | Article 40
